近日，福瑞达交出了一份承压的2025中期成绩单：上半年营收17.9亿元同比降7.05%，归母净利润1.08亿元同比降15.16%。 曾经撑起转型半边天的化妆品板块成为业绩拖累，其中核心品牌之一的瑷尔博士2025上半年营收同比骤降 29.97%，业务调整带来的阵痛还在持 续；寄予厚望的线下渠道拓展未达预期，营收占比不升反降；新押注的胶原蛋白医美赛道，旗下珂谧品牌尚未形成规模效应…… 不仅如此，在外部福瑞达还要面临传统美妆品牌与新兴品牌的激烈竞争，内外压力交织下如何突破转型阵痛期、重构增长动能，成为福瑞达亟待解 决的核心课题。 营收净利双降，瑷尔博士成最大拖累 从2025年福瑞达中报披露的数据来看，公司营收和净利润的双降主要来自于公司主要业务板块业务的下滑。 其中，除物业管理业务外的三大核心业务板块呈现明显分化，而化妆品板块的颓势直接主导了上市公司业绩走向。作为占总营收超60%的业绩"压舱 石"，化妆品业务上半年收入10.94亿元，同比减少7.73%，其中贡献最大的瑷尔博士品牌同比下滑29.97%，成为拖累业绩的核心因素。 尽管同板块内颐莲品牌表现亮眼，上半年营收5.54亿元同比增长23.78%，反超瑷尔博士，喷 ...

Investment Rating - The report maintains a "Recommended" rating for the company, with expected profit growth rates of 5.6%, 21.9%, and 25.0% for the years 2025 to 2027 respectively, corresponding to PE ratios of 33X, 27X, and 22X [4]. Core Insights - The company reported a revenue of 1.79 billion yuan in H1 2025, a decrease of 7.05% year-on-year, with a net profit attributable to shareholders of 108 million yuan, down 15.16% year-on-year [1]. - The cosmetics segment showed strong growth, particularly the Yilian brand, which achieved a revenue of 554 million yuan, up 23.78% year-on-year, driven by marketing initiatives and innovative sales channels [2]. - The report highlights a strategic adjustment in product offerings and a focus on brand positioning, particularly for the Aierbo brand, which faced revenue decline due to product iteration and pricing control [2]. Financial Performance Summary - In H1 2025, the company's gross margin was 52.35%, with a net profit margin of 6.03%. The gross margin improved by 0.48 percentage points year-on-year [3]. - The company’s revenue for Q2 2025 was 913 million yuan, a decline of 11.72% year-on-year, with a net profit of 57.25 million yuan, down 16.07% year-on-year [1]. - The report projects total revenue for 2025 to be 4.568 billion yuan, with a growth rate of 14.7% expected in 2026 [5][8].

风险提示：政策风险变动，产品研发不及预期，行业竞争加剧。 证券之星数据中心根据近三年发布的研报数据计算，东北证券李森蔓研究员团队对该股研究较为深入，近 三年预测准确度均值为41.08%，其预测2025年度归属净利润为盈利2.96亿，根据现价换算的预测PE为 29.14。 民生证券股份有限公司解慧新近期对福瑞达（600223）进行研究并发布了研究报告《2025年半年报点评： 颐莲高增，关注战略调整与产品迭代》，给予福瑞达买入评级。 福瑞达 事件：福瑞达发布2025年半年度报告。25H1公司实现营收17.90亿元，同比-7.05%；归母净利润1.08亿 元，同比-15.16%；扣非归母净利润1.05亿元，同比-6.25%。25Q2公司实现营收9.13亿元，同比-11.72%； 归母净利润5725.12万元，同比-16.07%；扣非归母净利润5759.17万元，同比-3.26%。 短期业绩略有承压，期待后续调整回升。分业务来看：25H1，1)化妆品业务，实现营业收入10.94亿元， 同比减少7.73%，主要系化妆品瑗尔博士品牌多款核心单品处于产品迭代阶段、线上流量红利减退、OEM 产品部分客户因经营不善流失等多种因 ...

2025 年 08 月 25 日 福瑞达 (600223) —— 25Q2 业绩承压，预计 25H2 在新品带动下提速 报告原因：有业绩公布需要点评 增持（下调） | 市场数据： | 2025 年 08 月 22 日 | | --- | --- | | 收盘价（元） | 8.52 | | 一年内最高/最低（元） | 9.42/5.74 | | 市净率 | 2.1 | | 股息率%（分红/股价） | 1.29 | | 流通 A 股市值（百万元） | 8,661 | | 上证指数/深证成指 | 3,825.76/12,166.06 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 4.08 | | 资产负债率% | 19.34 | | 总股本/流通 A 股（百万） | 1,017/1,017 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 上 市 公 司 美容护理 08-22 09-22 10-22 11-22 12-22 01-22 02-22 03-22 04 ...

Core Viewpoint - The company's performance is under short-term pressure due to strategic adjustments, with a decline in revenue and net profit in the first half of 2025 compared to the previous year [1] Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 1.79 billion yuan, down 7.05% year-on-year, and a net profit attributable to shareholders of 108 million yuan, down 15.16% year-on-year [1] - In Q2 2025, the company reported revenue of 914 million yuan, a decrease of 11.72% year-on-year, and a net profit of 57 million yuan, down 16.07% year-on-year [1] Group 2: Cosmetics Segment - The cosmetics segment generated revenue of 568 million yuan in Q2 2025, down 11.5% year-on-year, with a gross margin of 62.85%, an increase of 2.2 percentage points year-on-year [1] - The Yilian brand achieved revenue of 304 million yuan in Q2, up 23.08% year-on-year, benefiting from successful marketing activities [1] - The Ai'er Doctor brand reported revenue of 215 million yuan in Q2, down 38.75% year-on-year, currently undergoing a strategic adjustment [1] - The new brand Kemi performed well, with sales of collagen products exceeding 14 million yuan in the first half of the year [1] Group 3: Pharmaceutical Segment - The pharmaceutical segment's revenue in Q2 2025 was 99 million yuan, down 24.4% year-on-year, with a gross margin of 48.53%, a decrease of 1.3 percentage points year-on-year [2] Group 4: Raw Materials and Additives Segment - The raw materials and additives segment achieved revenue of 93 million yuan in Q2 2025, up 5.3% year-on-year, with a gross margin of 42.22%, down 6.2 percentage points year-on-year [3] - The growth in this segment was driven by product structure optimization, while the decline in gross margin was due to intensified industry competition [3] - The hyaluronic acid raw material business generated revenue of 116 million yuan in the first half of the year, up 23.4% year-on-year, with high-margin pharmaceutical-grade hyaluronic acid sales increasing significantly [3] Group 5: Overall Financial Metrics - In Q2 2025, the company's gross margin and net profit margin were 53.35% and 7.80%, respectively, with a year-on-year increase of 0.60 percentage points and a decrease of 0.24 percentage points [3] - The overall expense ratio increased due to revenue pressure, with sales, management, and R&D expense ratios rising year-on-year [3] - The company's operational capability and cash flow remained stable [3]

证券研究报告 | 2025年08月24日 福瑞达（600223.SH） 优于大市 战略调整致业绩短期承压，期待下半年新品表现 业绩受战略调整短期承压。公司 2025 年上半年实现营业收入 17.90 亿元 /yoy-7.05%；归母净利润 1.08 亿元/yoy-15.16%。单 Q2 实现营业收入 9.14 亿元/yoy-11.72%，实现归母净利润 0.57 亿元/yoy-16.07%。 化妆品板块 2025Q2 化妆品业务实现营收 5.68 亿/yoy-11.5%，毛利率 62.85%/yoy+2.2pct，其中颐莲品牌 Q2 实现 3.04/yoy+23.08%，受益于官宣 全球代言人张凌赫、举办夏日喷雾节等成功营销活动，上半年喷雾品线销售 额达 4.82 亿/yoy+43%，保持强劲增长势头；瑷尔博士 Q2 实现 2.15 亿 /yoy-38.75%，目前仍处于战略调整期，为维护价格体系严控渠道发货，业 绩短期承压，但品牌于 7 月推出王浆酸精研金致系列，有望带动下半年业绩 修复。此外，新锐品牌珂谧表现突出，胶原次抛上半年销售额超过 1400 万。 药品板块 2025Q2 实现营收 0.99 亿/y ...

美容护理/化妆品 福瑞达（600223.SH） 2025 年 08 月 24 日 投资评级：买入（维持） | 日期 | 2025/8/22 | | --- | --- | | 当前股价(元) | 8.52 | | 一年最高最低(元) | 9.42/5.74 | | 总市值(亿元) | 86.61 | | 流通市值(亿元) | 86.61 | | 总股本(亿股) | 10.17 | | 流通股本(亿股) | 10.17 | | 近 3 个月换手率(%) | 142.06 | 股价走势图 数据来源：聚源 -16% 0% 16% 32% 48% 64% 2024-08 2024-12 2025-04 福瑞达 沪深300 相关研究报告 《剔除地产业绩表现稳健，期待化妆 品业务稳中有升—公司信息更新报 告》-2025.3.26 《2024Q3 归母净利润同比-7.8%，化 妆品业务表现稳健—公司信息更新报 告》-2024.10.29 《剔除地产业务影响，2024H1 公司经 营情况稳健—公司信息更新报告》 -2024.8.24 2025 H1 业绩承压，期待化妆品业务调整修复 ——公司信息更新报告 公司发布半年报：20 ...

事件：公司发布2025 年中报。公司1H25 收入17.89 亿元（同比-7.1%，下同），归母净利润1.08 亿元 （-15.2%），扣非归母净利润1.05 亿元（-6.3%）；其中2Q25 收入9.13 亿元（-11.7%），归母净利润 0.57 亿元（-16.1%）。 风险提示：竞争加剧风险；化妆品销售不及预期风险；渠道拓展不及预期风险。 投资建议：公司坚持构建美与大健康生态体系，上半年颐莲品牌增势较好，原料业务贡献增长基本盘， 品牌建设稳步推进，期待瑷尔博士品牌调整完毕带动业绩修复。预计2025-2027 年归母净利润分别为 2.60/2.97/3.39 亿元，对应PE为33.3/29.1/25.6，维持"增持"评级。 化妆品业务颐莲实现高增，原料业务表现稳健。分业务看，1H25 化妆品实现收入10.94 亿元 （-7.7%），毛利率为62.0%（+0.6pct)，其中颐莲、瑷尔博士收入分别为5.54 亿元（+23.8%）/4.51 亿元 （-30.0%）；医药产品1H25实现收入2.07 亿元（-13.9%），毛利率51.8%（-0.3pct)；原料及衍生产品、 添加剂业务实现收入1.79 亿元（+ ...

Core Insights - The company reported a revenue of 1.79 billion yuan in the first half of 2025, with a net profit of 108 million yuan, and total assets of 6.037 billion yuan as of June 30, 2025 [1][2] Group 1: Cosmetics Business - The cosmetics segment generated a revenue of 1.094 billion yuan in the first half of 2025, with the Yilian brand achieving 554 million yuan, reflecting a year-on-year growth of 23.78% [2] - The Yilian brand launched a global spokesperson, Zhang Linghe, and held a summer spray festival, with spray product line sales reaching 482 million yuan, an increase of 43% [2] - The Aier Doctor brand reported a revenue of 451 million yuan, with new products like the 287 mask and 287 lotion, generating nearly 10 million yuan in sales within two months of launch [2] Group 2: Pharmaceutical Business - The pharmaceutical segment achieved a revenue of 207 million yuan, expanding its client base by over 200 hospitals and OTC customers [2] - Key products include children's flu medication and a popular pain relief product recognized at the Wuzhen Health Conference [2] - The company is actively developing food-medicine integration standards and collaborating with major clients to enhance raw material supply [2] Group 3: Raw Materials and Additives - The raw materials and additives segment reported a revenue of 179 million yuan, with hyaluronic acid sales reaching 116 million yuan, a year-on-year increase of 23.4% [3] - Medical-grade hyaluronic acid sales surged by 287.3%, totaling 16.08 million yuan [3] - The overall gross margin for the hyaluronic acid business improved to 47.1%, up by 8.5 percentage points [3] Group 4: Innovation and R&D - The company launched over 80 new products in the cosmetics sector, including the Aier Doctor 287 mask and Yilian purple essence water [3] - The company introduced a pioneering transdermal collagen technology, enhancing skin penetration by 27.5 times [3] - The company has made significant progress in medical device registrations and drug development, including obtaining production licenses for various products [3]

Group 1: Core Insights - The press conference focused on showcasing the achievements and innovations of high-quality products from Shandong, aiming to enhance the brand's presence nationally and globally [1] - The Shandong government emphasizes brand development through the "Good Products Shandong" strategy, which aims to cultivate competitive brands to increase product value and market share [1] Group 2: Company Highlights - Furuida (600223) has developed a comprehensive supply chain in the cosmetics industry, achieving multiple industry firsts and holding over 170 patents, with its flagship product, the Yilian spray, selling over 50 million bottles annually [2] - Hisense Group has transformed from a small local factory to a multinational corporation, ranking second globally in TV shipments for three consecutive years and leading in several countries, while also expanding into high-tech industries [3] - Huaguang National Porcelain Technology Co., Ltd. has pioneered advanced ceramic materials and technologies, achieving international standards that surpass British bone china, and has been involved in significant national diplomatic events [4] - Lubao Group has innovated in the edible oil sector with its patented 5S physical pressing technology, enhancing peanut oil quality and developing high oleic peanut varieties, contributing to a green circular economy [5] Group 3: Brand Development Strategies - The conference served as a platform for discussing new paths and trends in brand development, emphasizing the need for continuous technological innovation and quality enhancement to maintain competitiveness [6] - Experts agreed on the importance of brand promotion and international cooperation to elevate the global presence of Shandong products [6] - The Shandong government plans to enhance the brand cultivation system and provide policy support to create a favorable environment for brand development [7]